Will I look back and regret not buying CSL shares at $237 today?

Is buying CSL shares today akin to catching a falling knife? Or will I regret not buying the healthcare stock at just over $237?

| More on:
Shot of a scientist recording his findings on a digital tablet.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are up 0.4% in afternoon trade on Wednesday.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock are currently changing hands for $237.35 apiece.

Despite that tick higher, the CSL share price remains down 15.8% since the opening bell on 3 January.

That compares to a 1.8% gain posted by the ASX 200 over this same time.

So, is buying CSL shares today akin to catching a falling knife?

Or will I regret not buying the healthcare stock at just over $237?

What's the outlook for CSL shares?

While the future is uncertain by definition, the majority of analysts are bullish on the one-year outlook for CSL shares.

Despite having a neutral rating on the stock, Goldman Sachs has a $296 12-month price target on its shares.

Citi's analysts are even more bullish, with a buy rating and a $325 price target. That represents a 37% upside from where CSL shares are trading at today.

Neither broker appears too concerned about the potential competition from Novo Nordisk's weight loss drug Ozempic to treat kidney disorders and other related illnesses, which could take a bite out of CSL's business.

CSL is still working to bring costs down to get its gross margins back up to pre-COVID levels.

On that front, CEO Paul McKenzie recently noted, "We are making genuine inroads, but there is more to do and it's just going to take some time."

More broadly, Janus Henderson Investors portfolio manager Andy Acker believes the healthcare sector's long-term outlook "appears stronger than ever".

"We think this is an attractive time to be investing in the healthcare sector," Acker said.

And last week CSL provided some promising FY 2024 guidance during the company's annual general meeting, though CSL shares dipped on the day.

The biotech stock is forecasting year on year revenue growth of 9% to 11%.

And FY 2024 guidance for net profit after tax and amortisation (NPATA) was forecast to come in between US$2.9 billion to US$3 billion on a constant currency basis. That translates to a year on year profit boost of 13% to 17%.

Time to buy?

So, will I regret not buying CSL shares at just over $237 today?

It appears that I might.

While I'm not jumping into the stock today, it's certainly high on my watchlist.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »